3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
196
Myelodysplastic Syndromes
128
Precursor Cell Lymphoblastic Leukemia-Lymphoma
123
Leukemia, Lymphocytic, Chronic, B-Cell
102
Leukemia
102
Lymphoma
86
Multiple Myeloma
81
Lymphoma, Non-Hodgkin
80
Hematologic Neoplasms
65
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
62
Hodgkin Disease
62
Recurrence
52
Lymphoma, B-Cell
40
Lymphoma, Mantle-Cell
39
Myeloproliferative Disorders
36
Lymphoma, Follicular
35
Melanoma
34
Lymphoma, Large B-Cell, Diffuse
31
Burkitt Lymphoma
31
Graft vs Host Disease
28
Neoplasms, Plasma Cell
24
Primary Myelofibrosis
23
Ovarian Neoplasms
23
Lymphoma, B-Cell, Marginal Zone
23
Anemia, Refractory, with Excess of Blasts
21
Leukemia, Myelomonocytic, Chronic
20
Leukemia, Biphenotypic, Acute
17
Lymphoma, T-Cell
16
Neuroblastoma
15
Neoplasms
14
Interventions
Magnetic Resonance Spectroscopy
12
gallium Ga 68 dotatate
6
Everolimus
6
lutetium Lu 177 dotatate
5
Radiosurgery
5
Proton Therapy
5
Bevacizumab
5
pembrolizumab
4
Surveys and Questionnaires
4
Specimen Handling
4
Hydroxyurea
4
abemaciclib
3
Tranexamic Acid
3
Surgical Procedures, Operative
3
Sodium Chloride
3
Ga(III)-DOTATOC
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
vistusertib
2
trametinib
2
ribociclib
2
arginyllysine
2
aldesleukin
2
Yoga
2
Whole Body Imaging
2
Sunitinib
2
Saline Solution
2
Ropivacaine
2
Radiotherapy
2
Protons
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Meningioma
×
fludarabine
×
Clear all
NCT06640582
2024-11-05
BAH2472
Essen Biotech
Phase 1/2
Recruiting
85 enrolled